Zobrazeno 1 - 10
of 237
pro vyhledávání: '"Stephen Caddick"'
Autor:
Késsia H. S. Andrade, Jaime A. S. Coelho, Raquel Frade, Ana M. Madureira, João P. M. Nunes, Stephen Caddick, Rafael F. A. Gomes, Carlos A. M. Afonso
Publikováno v:
ChemMedChem.
Autor:
Ninfa L. Straubinger, Stephen Caddick, Daniel B. Longley, James F Burrows, Darren K.W. Chan, Charlene Minx, Michelle K. Greene, Jun Wang, Robert M. Straubinger, Sandra Van Schaeybroeck, James R. Baker, Vijay Chudasama, Eifion Robinson, Ting Chen, Christopher J. Scott, Donald E. Mager
Publikováno v:
Greene, M K, Chen, T, Robinson, E, Straubinger, N L, Minx, C, Chan, D K W, Wang, J, Burrows, J F, Van Schaeybroeck, S, Baker, J R, Caddick, S, Longley, D B, Mager, D E, Straubinger, R M, Chudasama, V & Scott, C J 2020, ' Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer ', British Journal of Cancer . https://doi.org/10.1038/s41416-020-01046-6
British Journal of Cancer
British Journal of Cancer
Background Antibody-drug conjugate (ADC) construction poses numerous challenges that limit clinical progress. In particular, common bioconjugation methods afford minimal control over the site of drug coupling to antibodies. Here, such difficulties ar
Autor:
Peter A. Szijj, Vijay Chudasama, James R. Baker, Stephen Caddick, Antoine Maruani, João C. F. Nogueira, Calise Bahou
Publikováno v:
Bioconjugate Chemistry. 31:520-529
Diseases are multifactorial, with redundancies and synergies between various pathways. However, most of the antibody-based therapeutics on the market interact with only one target, thus limiting their efficacy. The targeting of multiple epitopes coul
Autor:
Antoine, Maruani, Peter A, Szijj, Calise, Bahou, João C F, Nogueira, Stephen, Caddick, James R, Baker, Vijay, Chudasama
Publikováno v:
Bioconjugate chemistry. 31(3)
Diseases are multifactorial, with redundancies and synergies between various pathways. However, most of the antibody-based therapeutics on the market interact with only one target, thus limiting their efficacy. The targeting of multiple epitopes coul
Autor:
Antoine Maruani, Stephen Caddick, Eifion Robinson, Mark E. B. Smith, João P. Nunes, Vessela Vassileva, James R. Baker, R. Barbara Pedley, João C. F. Nogueira, Vijay Chudasama
Publikováno v:
RSC Advances. 7:9073-9077
Herein we report the use of pyridazinediones to functionalise the native solvent accessible interstrand disulfide bonds in trastuzumab with monomethyl auristatin E (MMAE). This method of conjugation delivers serum stable antibody–drug conjugates (A
Autor:
Antoine Maruani, Peter A. Szijj, Calise Bahou, João C. F. Nogueira, Stephen Caddick, James R. Baker, Vijay Chudasama
Diseases are multifactorial, with redundancies and synergies between various pathways. However, most of the antibody-based therapeutics in clinical trials and on the market interact with only one target thus limiting their efficacy. The targeting of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5de0949899ca70dd94042ccb23164ed9
https://doi.org/10.26434/chemrxiv.8068184
https://doi.org/10.26434/chemrxiv.8068184
Autor:
Maurício Morais, João P. M. Nunes, Kersti Karu, Nafsika Forte, Irene Benni, Mark E. B. Smith, Stephen Caddick, Vijay Chudasama, James R. Baker
Publikováno v:
Organic & Biomolecular Chemistry. 19:3024-3024
Correction for ‘Optimisation of the dibromomaleimide (DBM) platform for native antibody conjugation by accelerated post-conjugation hydrolysis’ by Maurício Morais et al., Org. Biomol. Chem., 2017, 15, 2947–2952, DOI: 10.1039/C7OB00220C.
Autor:
Vanessa D’Antongiovanni, Manuela Platé, Rachel C. Chambers, Eifion Robinson, Alejandro Ortiz Stern, Vijay Chudasama, Chris J. Scotton, Gabor Jarai, Stephen Caddick, Natalia Smoktunowicz
Publikováno v:
Oncotarget
// Natalia Smoktunowicz 1 , Manuela Plate 1 , Alejandro Ortiz Stern 1 , Vanessa D’Antongiovanni 1 , Eifion Robinson 2 , Vijay Chudasama 2 , Stephen Caddick 2 , Chris J. Scotton 1 , Gabor Jarai 3 , Rachel C. Chambers 1 1 Centre for Inflammation and
Publikováno v:
Nature Chemistry. 8:114-119
Antibody-drug conjugates (ADCs) comprise antibodies covalently attached to highly potent drugs using a variety of conjugation technologies. As therapeutics, they combine the exquisite specificity of antibodies, enabling discrimination between healthy
Autor:
Vijay Chudasama, Natalia Smoktunowicz, Graham G. Inglis, Eifion Robinson, Stephen Caddick, Emily Knight, Rachel C. Chambers
Publikováno v:
Organic & Biomolecular Chemistry. 14:3198-3201
The discontinuation of PAR-1 antagonist RWJ-58259 beyond use as a biological probe is most likely due to it's short half-life in vivo. However, retention of significant in vivo activity beyond the point where most of the RWJ-58259 had been consumed i